Aura Biosciences (NASDAQ:AURA) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen has upgraded Aura Biosciences (NASDAQ:AURA) from a "sell" to a "hold" rating, contributing to the stock's overall consensus "Hold" rating with an average target price of $20.50. Despite mixed analyst views, the company reported a Q1 EPS of ($0.37), beating estimates. However, corporate insiders recently sold a significant number of shares, indicating a reduction in their positions.
Wall Street experts forecast a potential 201.49% increase for Aura Biosciences (AURA): Key information you need to know
Aura Biosciences (AURA) has recently seen an 8.9% increase in its stock price, with Wall Street analysts projecting a further 201.5% upside based on an average price target of $20.20. While analyst price targets should be approached with caution, strong consensus among analysts and recent upward revisions in earnings estimates suggest positive momentum. AURA also holds a Zacks Rank #2 (Buy), indicating strong near-term potential.
Wall Street experts forecast a potential 201.49% increase for Aura Biosciences (AURA): Key information you need to know
Aura Biosciences (AURA) recently saw an 8.9% increase, with Wall Street analysts projecting a further 201.5% upside, targeting an average of $20.20. Despite potential optimism biases in analyst targets, increased analyst confidence in AURA's earnings outlook and its Zacks Rank #2 (Buy) suggest strong near-term potential. Investors are advised to use price targets as a starting point for further research rather than the sole basis for decisions.
FY2030 Earnings Forecast for AURA Issued By HC Wainwright
HC Wainwright has issued its FY2030 earnings forecast for Aura Biosciences (NASDAQ:AURA), predicting earnings per share of ($0.35) and maintaining a "Buy" rating with a $22 price target. This forecast is significantly higher than the consensus estimate of ($1.66) per share. Despite the positive outlook from HC Wainwright and analysts' average target price of $20.50, the stock is currently trading around $6.70, and recent insider activity shows sales of company shares.
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Aura Biosciences reported its financial results for the fourth quarter and full year 2025, highlighting significant progress in its clinical trials. The company accelerated enrollment for its Phase 3 CoMpass trial for early choroidal melanoma, expecting completion by mid-2026 and topline data in late 2027. Additionally, initial 3-month clinical data from the Phase 1b/2 NMIBC trial is anticipated mid-2026, and a new stable formulation for non-ocular solid tumors was announced.
Aura Biosciences (NASDAQ:AURA) Earns Buy Rating from HC Wainwright
HC Wainwright reissued a "Buy" rating for Aura Biosciences (NASDAQ:AURA) with a $22 price target, indicating a potential 250% upside. The company's Q1 earnings of ($0.37) per share surpassed estimates, but analysts still forecast a full-year loss. While insiders have recently sold shares, institutional investors and hedge funds hold a significant 96.75% ownership.
Bel-sar pipeline data and cash risks in Aura Biosciences (NASDAQ: AURA) 10-K
Aura Biosciences' annual report details bel-sar, a virus-like drug conjugate, in Phase 3 for early choroidal melanoma and early-phase trials for other ocular and bladder cancers. Despite promising early clinical data, the company has recurring losses, expects continued losses, and its auditors issued a "going concern" opinion due to heavy dependence on future financings and bel-sar's clinical success. Key risks highlighted include reliance on a single product, clinical and regulatory uncertainty, and the need for substantial additional capital to fund operations.
Aura Biosciences 10-K: $0 Revenue, $(106.2)M Net Loss
Aura Biosciences reported zero revenue and a net loss of $(106.2) million for the year ended December 31, 2025, primarily due to its pre-revenue clinical-stage operations and increased trial costs. The company's loss from operations expanded to $(112.8) million, driven by higher R&D expenses. Despite ongoing equity offerings to fund development, Aura Biosciences expressed substantial doubt about its ability to continue as a going concern for the next 12 months.
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Aura Biosciences reported its financial results for Q4 and full year 2025, highlighting significant progress in clinical trials. The company accelerated enrollment in its Phase 3 CoMpass trial for early choroidal melanoma, with topline data expected in H2 2027, and announced initial clinical data from its Phase 1b/2 NMIBC trial is anticipated mid-2026. Aura Biosciences also achieved 12-month stability for a new formulation for non-ocular solid tumors, reinforcing its potential for broader applications.
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Aura Biosciences announced its financial results for Q4 and full year 2025, highlighting significant progress in its clinical trials. The company accelerated enrollment in its Phase 3 CoMpass trial for early choroidal melanoma, with topline data expected in H2 2027, and its Phase 1b/2 NMIBC trial is on track for initial data mid-2026. Aura Biosciences reported cash and equivalents of $144.2 million, sufficient to fund operations into Q1 2027.
Aura Biosciences (NASDAQ: AURA) details 2025 loss, cash runway to Q1 2027 and bel-sar trial timelines
Aura Biosciences reported a net loss of $106.2 million for 2025, an increase from $86.9 million in 2024, primarily due to higher R&D expenses for its advancing oncology pipeline. The company holds $144.2 million in cash, which is expected to fund operations into Q1 2027. Key clinical trial updates include accelerated enrollment for the Phase 3 CoMpass trial in early choroidal melanoma, with topline data anticipated in H2 2027, and initial three-month data from a Phase 1b/2 trial in non-muscle-invasive bladder cancer expected mid-2026.
Aura says eye melanoma Phase 3 enrollment now points to 2027 data
Aura Biosciences announced its Q4 and full-year 2025 financial results and program updates. The company now expects to complete enrollment for its Phase 3 CoMpass trial for early choroidal melanoma by mid-2026, with topline data anticipated in the second half of 2027. Aura reported $144.2 million in cash and marketable securities, providing a runway into Q1 2027, despite increased R&D expenses and a widened net loss for 2025.
(AURA) Movement as an Input in Quant Signal Sets
The article analyzes Aura Biosciences Inc. (NASDAQ: AURA) using AI-generated quantitative signals, indicating conflicting sentiment and a mid-channel oscillation pattern. It presents three trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. Key findings include an exceptional risk-reward short setup and multi-timeframe signal analysis for near-term, mid-term, and long-term horizons, highlighting support and resistance levels.
Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Rating of "Hold" by Brokerages
Five brokerages have given Aura Biosciences (NASDAQ:AURA) an average rating of "Hold," with three recommending a "buy," one a "hold," and one a "sell." The average 12-month target price is $20.50, significantly higher than the stock's recent open of $6.44. Insiders have recently sold shares, while institutional ownership remains very high at 96.75%, with major firms increasing their stakes.
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update
Aura Biosciences (NASDAQ:AURA) experienced a 22.0% decrease in short interest in February, totaling 2,249,277 shares, which represents approximately 3.8% of the company's float. The days-to-cover ratio stands at 10.8 days based on average trading volume. Despite some insider selling of shares worth $618,783, institutional investors and hedge funds hold a significant 96.75% stake, and analysts have a "Moderate Buy" consensus rating with a target price of $20.50.
Aura Biosciences (AURA) to Release Earnings on Monday
Aura Biosciences (NASDAQ:AURA) is scheduled to release its Q4 2025 earnings before market open on Monday, March 23rd, with analysts anticipating a loss of ($0.43) per share. The company's shares recently traded at $6.77, and analysts have a "Moderate Buy" rating with an average price target of $20.50. Insider sales and institutional ownership are notable, with insiders selling 123,076 shares in the last 90 days and institutions holding approximately 96.75% of the stock.
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Lisata Therapeutics Inc. (NASDAQ: LSTA) shares surged over 20% in pre-market trading after announcing an agreement to be taken private by Kuva Labs at $5.00 per share plus a $1.00 contingent value right. The article also details other significant pre-market movers, including gainers like Hims & Hers Health Inc. (NYSE: HIMS) and EON Resources Inc. (NYSE: EONR), and losers such as Zymeworks Inc. (NASDAQ: ZYME) and Olema Pharmaceuticals Inc. (NASDAQ: OLMA). Key factors driving these movements include acquisition news, partnership announcements, and financial results.
12 Health Care Stocks Moving In Monday's Pre-Market Session
This article lists 12 health care stocks that experienced significant movement in Monday's pre-market session. It highlights both gainers, such as Relmada Therapeutics and Hims & Hers Health, and losers, including Olema Pharmaceuticals and Zymeworks, noting their percentage change and market capitalization. The article provides a snapshot of early market activity for these specific health care companies.
12 Health Care Stocks Moving In Monday's Pre-Market Session
This article lists 12 healthcare stocks that are experiencing significant movement in Monday's pre-market session. It highlights both gainers and losers, including companies like Relmada Therapeutics, Hims & Hers Health, Xenon Pharmaceuticals, Olema Pharmaceuticals, and Zymeworks, along with their respective percentage changes and market capitalizations.
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Lisata Therapeutics shares jumped over 20% in pre-market trading after the company announced an agreement to be taken private by Kuva Labs at $5.00 per share plus a contingent value right. The article also highlights other significant pre-market movers, including Hims & Hers Health, EON Resources, and Atara Biotherapeutics, detailing their respective news or recent trading actions which contributed to their stock movements. Conversely, stocks like Zymeworks and Olema Pharmaceuticals experienced declines.
Why (AURA) Price Action Is Critical for Tactical Trading
This article analyzes Aura Biosciences Inc. (NASDAQ: AURA), highlighting strong near and mid-term sentiment despite a weak long-term outlook. It identifies an exceptional risk-reward setup targeting a 13.7% gain against 0.4% risk and outlines three distinct AI-generated trading strategies for different risk profiles and holding periods, including position trading, momentum breakout, and risk hedging strategies. The analysis emphasizes the importance of AURA's price action for tactical trading, referencing specific entry, target, and stop-loss levels.
Aura Biosciences (AURA) officer receives RSU and option grants
Aura Biosciences officer Anthony S. Gibney received new equity awards, including 71,245 restricted stock units and a stock option for 128,755 shares, as reported in a recent SEC Form 4 filing. These awards are subject to vesting schedules contingent on his continued service with the company. The RSUs vest annually starting January 15, 2027, while the stock option vests 25% on February 1, 2027, with the remainder vesting monthly thereafter.
Aura Biosciences Touts Phase 3 bel-sar Momentum, Eyes Mid-Year Bladder Cancer Data at TD Cowen Conference
Aura Biosciences (NASDAQ: AURA) provided updates on its lead program, bel-sar for early-stage choroidal melanoma, emphasizing strong Phase 3 enrollment and a target for top-line data in Q4 2027. The company also anticipates mid-year data from a neoadjuvant bladder cancer study, highlighting promising immune activation and favorable tolerability. Aura aims to broaden its market opportunity by expanding into additional ocular indications and pursuing innovative treatment approaches for various cancers.
Aura's Bel-sar — One Asset, Multiple Oncology Opportunities
Aura Biosciences Inc. (AURA) is developing Belzupacap Sarotalocan (Bel-sar) for multiple oncology indications. The drug is currently in a global Phase 3 trial for early-stage choroidal melanoma, a rare intraocular cancer, with topline data expected in Q4 2027. Aura is also investigating Bel-sar for choroidal metastasis and non-muscle-invasive bladder cancer, with early proof-of-concept data anticipated in 2026 for both.
Aura Biosciences (AURA) SVP awarded 80,472 options and 44,528 RSUs
Aura Biosciences, Inc.'s Senior Vice President of Finance, Amy Elazzouzi, was granted 80,472 stock options and 44,528 restricted stock units (RSUs) as compensation. These equity awards, granted at an exercise price of $0.00, are subject to vesting schedules contingent on her continued service with the company. The RSUs vest in four annual installments starting January 15, 2027, while the stock options begin vesting on February 1, 2027, with 25% initially and the remainder over 36 monthly installments.
Large equity awards to Elisabet de los Pinos at Aura Biosciences (AURA)
Elisabet de los Pinos, a director and officer at Aura Biosciences (AURA), received significant equity awards on March 2, 2026. These awards include 166,000 restricted stock units (RSUs) and an option to purchase 249,000 shares of Common Stock, both with a grant/exercise price of $0.0000. These awards are subject to multi-year vesting schedules contingent on her continued service, significantly increasing her beneficial ownership in the company.
Aura Biosciences (AURA) grants stock options and RSUs to its CMO
Aura Biosciences announced that its Chief Medical Officer, Janet Jill Hopkins, received new equity awards, including a stock option for 160,944 shares and 89,056 restricted stock units (RSUs), both at an exercise price of $0.00 per share. These awards were granted under the company's 2021 Stock Option and Incentive Plan. The RSUs vest in four equal annual installments starting January 15, 2027, while the stock options vest 25% on February 1, 2027, with the remainder vesting monthly, all contingent on continued service.
Aura Biosciences (AURA) CTO receives new stock option and RSU awards
Aura Biosciences' Chief Technology Officer, Mark Plavsic, has received new equity awards, including a stock option for 112,661 shares and 62,339 Restricted Stock Units (RSUs), as detailed in a recent SEC Form 4 filing. The RSUs will vest in four equal annual installments starting January 15, 2027, while the stock options vest 25% on February 1, 2027, with the remainder vesting monthly over 36 installments. Both awards are contingent on his continued service to the company.
Aura Biosciences (AURA) officer granted RSUs and 112,661-share option
Conor Kilroy, an officer at Aura Biosciences (AURA), was granted a stock option for 112,661 shares and an award of 62,339 restricted stock units (RSUs) on March 2, 2026. The RSUs will vest in four equal annual installments starting January 15, 2027, while the stock option vests 25% on February 1, 2027, with the remainder vesting monthly, all contingent on continued service. These awards increase his direct ownership to 229,573 common shares and 112,661 option shares.
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Moderate Buy" from Analysts
Aura Biosciences Inc. (NASDAQ:AURA) has received an average rating of "Moderate Buy" from six analysts, with an average one-year price target of $20.50, significantly higher than its current share price of $5.89. Insider activity shows sales totaling $618,783 over the past 90 days, though insiders still hold 6.30% of the stock. Aura Biosciences is a clinical-stage biopharmaceutical company developing virus-like particle photodynamic therapies, with its lead candidate AU-011 being evaluated for choroidal melanoma.
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences, Inc. announced that its senior management team will participate in three upcoming investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference, the Leerink Partners Global Healthcare Conference, and The Citizens Life Sciences Conference. Live webcasts and archived replays of the fireside chats will be available on the company's website. Aura Biosciences is a clinical-stage biotechnology company developing precision therapies for solid tumors, with its lead candidate bel-sar in development for choroidal melanoma and other indications.
Aura Biosciences plans fireside chats at three March healthcare events
Aura Biosciences (NASDAQ: AURA) announced its senior management will participate in three investor conferences in March 2026, featuring live fireside chats and webcasts. The events include the TD Cowen 46th Annual Health Care Conference, Leerink Partners Global Healthcare Conference, and The Citizens Life Sciences Conference. Webcasts will be accessible on the company's Investors & Media page, with replays archived for 90 days.
Understanding Momentum Shifts in (AURA)
This article analyzes Aura Biosciences Inc. (NASDAQ: AURA), indicating weak sentiment across all time horizons which supports a short bias. It highlights a significant 44.0:1 risk-reward short setup targeting 15.7% downside with minimal risk, and details various AI-generated trading strategies including long, breakout, and hedging options. The analysis also provides multi-timeframe signal strengths, support, and resistance levels for the stock.
Form 4: Elazzouzi Amy reports sale transactions in AURA
Amy Elazzouzi, Senior Vice President of Finance at Aura Biosciences (AURA), reported the sale of 8,549 shares at a weighted average price of $5.06 per share, totaling approximately $43,257. These transactions were identified in a Form 4 SEC filing and were automatic sales made to cover tax withholding obligations related to the vesting of restricted stock units. Following these sales, Elazzouzi's direct holdings in Aura Biosciences stand at 75,532 shares.
Aura Biosciences (NASDAQ: AURA) director sold 17,109 shares
Aura Biosciences director Janet Jill Hopkins sold 17,109 shares of common stock for $92,734.66 on November 17, 2025, through Morgan Stanley Smith Barney LLC, as reported in a Form 144 filing. The filing also disclosed restricted stock unit awards granted on February 1, 2024, and February 3, 2025, that are subject to vesting requirements. This transaction is considered a routine disclosure under resale rules, with a neutral impact and sentiment indicated by Rhea-AI.
Ocular melanoma Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Delcath System, Aura Biosciences, Seagen, IDEAYA, Ascentage Pharma
The ocular melanoma market is expected to grow significantly by 2034, driven by increasing disease prevalence, awareness, and the launch of innovative pipeline products, especially those addressing unmet needs in metastatic cases. Key companies like Immunocore, Delcath Systems, and Aura Biosciences are developing advanced therapies, including targeted and immunotherapies, which are revolutionizing treatment options beyond traditional radiation and surgery, despite challenges such as low disease prevalence and high treatment costs. The market size was valued at approximately $340 million in 2023.
Aura Biosciences (NASDAQ:AURA) Insider Los Pinos Elisabet De Sells 47,648 Shares
Aura Biosciences (NASDAQ:AURA) insider Los Pinos Elisabet De sold 47,648 shares of the company's stock on February 17th at an average price of $5.06, totaling approximately $241,099. This transaction reduced her stake by 10.42% to 409,815 shares. The stock is currently trading near $5.25, below its 50 and 200-day moving averages, and holds a "Moderate Buy" consensus rating from analysts with a target price of $20.50.
Are Medical Stocks Lagging Assertio (ASRT) This Year?
Assertio (ASRT), a stock in the Medical sector, has significantly outperformed its peers and the sector as a whole, with a 36.4% year-to-date return compared to the sector's 1.9%. The company holds a Zacks Rank of #2 (Buy) due to improving analyst sentiment and earnings outlook. Aura Biosciences, Inc. (AURA) is another Medical stock showing strong performance this year.
Aura Biosciences (NASDAQ:AURA) Insider Sells $103,229.06 in Stock
Aura Biosciences insider Janet Jill Hopkins sold 20,401 shares of the company's stock for a total of $103,229.06, reducing her stake by 8.07%. Following the sale, Aura Biosciences' stock traded down 5.7% to $5.25. Despite this, institutional investors hold a significant portion of the stock, and analysts maintain a "Moderate Buy" consensus rating with a target price of $20.50.
Mark Plavsic Sells 15,890 Shares of Aura Biosciences (NASDAQ:AURA) Stock
Mark Plavsic, CTO of Aura Biosciences (NASDAQ:AURA), sold 15,890 shares of the company's stock on February 17, 2026, for a total of $80,244.50. This transaction reduced his direct holdings by 8.05%, leaving him with 181,397 shares. Aura Biosciences' shares traded down to $5.25, with institutional investors holding a significant portion of the stock.
Aura Biosciences (AURA) Form 144 lists 15,890-share proposed sale via Morgan Stanley
Aura Biosciences (AURA) has filed a Form 144, indicating a proposed sale of 15,890 shares of common stock through Morgan Stanley Smith Barney LLC. The filing, dated February 17, 2026, also details restricted stock unit awards granted in 2024 and 2025. It's important to note that a Form 144 is a notice of intent and does not confirm the actual execution of the sale.
Aura Biosciences, Inc. (AURA) Stock Analysis: Unpacking a 259% Potential Upside in Biotech Innovation
Aura Biosciences, Inc. (AURA) is presented as a clinical-stage biotech company with significant investment potential, offering a 259.43% upside according to analyst targets. Despite its current stock price nearing oversold territory and negative financial metrics typical of early-stage biotechs, the company's innovative virus-like drug conjugate platform and lead candidate, bel-sar, in late-stage clinical development, drive strong bullish sentiment among analysts. Investors seeking groundbreaking medical innovations and substantial returns may find AURA an appealing, though high-risk, option.
Avoiding Lag: Real-Time Signals in (AURA) Movement
This article analyzes Aura Biosciences Inc. (NASDAQ: AURA) using AI models to provide real-time trading signals and strategies. It highlights mixed sentiment, potential choppiness, and offers specific position trading, momentum breakout, and risk hedging strategies based on different risk profiles. The analysis includes support, resistance levels, and risk-reward ratios across various time horizons.
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Recommendation of "Moderate Buy" from Analysts
Aura Biosciences, Inc. (NASDAQ:AURA) has received an average "Moderate Buy" rating from six analysts, with a consensus one-year target price of $20.50. The company's shares opened at $5.75, showing a market capitalization of approximately $365 million and a negative P/E ratio. Insider selling of 35,618 shares has occurred in the past 90 days, while institutional investors hold a significant 96.75% of the stock.
Discipline and Rules-Based Execution in AURA Response
This article provides an analysis of Aura Biosciences Inc. (NASDAQ: AURA) highlighting near-term weak sentiment but mid-term strength within a broader long-term weak bias. It discusses resistance testing and an exceptional risk-reward short setup. The piece also details institutional trading strategies including position, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis generated by AI.
Aura Biosciences, Inc. (AURA): Investor Outlook with a Remarkable 257.93% Potential Upside
Aura Biosciences, a clinical-stage biotechnology company focused on precision therapies for solid tumors, is attracting significant investor attention due to its promising pipeline and a potential upside of 257.93%. The company's lead candidate, bel-sar, is in late-stage clinical development for ocular melanoma and early-stage trials for bladder cancer. Despite being pre-revenue with negative profitability metrics, analysts unanimously rate AURA as a "buy," with an average price target of $19.40, indicating substantial growth potential for risk-tolerant, long-term investors.
Aura Biosciences (NASDAQ:AURA) Insider Los Pinos Elisabet De Sells 16,928 Shares
Aura Biosciences (NASDAQ:AURA) insider Los Pinos Elisabet De sold 16,928 shares of the company's stock on January 20th for approximately $82,270, reducing her position by 3.57%. Following this transaction, she directly owns 457,463 shares valued at over $2.2 million. The stock traded down $0.05 to $4.97, with analysts holding a "Moderate Buy" consensus rating and a target price of $20.50.
Aura Biosciences SVP Amy Elazzouzi sells $7683 in stock By Investing.com
Amy Elazzouzi, SVP of Finance at Aura Biosciences (NASDAQ:AURA), sold 1,581 shares of common stock for $7,683 to cover tax withholding obligations related to restricted stock unit vesting. Following this automated transaction, Elazzouzi retains 84,081 shares. This news follows Evercore ISI's "Outperform" rating for Aura Biosciences and leadership changes at NovaBridge Biosciences' subsidiary, Visara.
Aura Biosciences SVP Amy Elazzouzi sells $7683 in stock
Amy Elazzouzi, Senior Vice President of Finance at Aura Biosciences (NASDAQ:AURA), sold 1,581 shares of common stock for $7,683 on January 20, 2026. This sale was a mandatory transaction to cover tax withholding obligations related to restricted stock unit vesting. Following the sale, Elazzouzi directly owns 84,081 shares of Aura Biosciences.
Aura Biosciences SVP Amy Elazzouzi sells $7683 in stock By Investing.com
Amy Elazzouzi, Senior Vice President of Finance at Aura Biosciences (NASDAQ:AURA), sold 1,581 shares of common stock for $7,683 on January 20, 2026. This sale was conducted to cover tax withholding obligations related to restricted stock units. In other company news, Evercore ISI resumed coverage on Aura Biosciences with an Outperform rating, and NovaBridge Biosciences announced leadership changes within its subsidiary, Visara.
